Abstract:Abstract Background The p38 alpha mitogen‐activated protein kinase (p38α) pathway is linked to both innate and adaptive immune responses, and is currently under investigation as a target for drug development in the context of Alzheimer’s disease (AD) and other conditions with neuroinflammatory dysfunction (Asih et al., 2020). Preclinical data indicates that p38α inhibition can protect against AD‐associated neuropathology, although the cellular mechanisms and signaling pathways that underlie these effects have not been fully elucidated. Evidence suggests that inhibition of p38α may provide benefit by modulating microglial‐associated neuroinflammatory processes that contribute to the development of AD pathology. The present study tests this hypothesis by assessing early‐stage pathological changes in AD model mice following microglial‐specific knock out (KO) of p38α. Methods KO of p38α in microglia was accomplished in 5‐month‐old C57BL/6J wild‐type and amyloidogenic AD model (APPswe/PS1dE9) mice using a tamoxifen‐inducible Cre/loxP system under control of the Cx3Cr1 promoter. Animals underwent behavioral assessment on the open field test at 7.5 months of age and on the radial arm water maze test at 11 months of age, followed by collection of cortical and hippocampal tissues. Other endpoint measures included quantification of proinflammatory cytokines, assessment of amyloid burden and plaque deposition, and characterization of microglia‐plaque dynamics using a combination of ELISA, immunohistochemical, and immunofluorescent techniques. Results Suppression of microglial p38α did not alter behavioral outcomes, proinflammatory cytokine levels, or overall amyloid plaque burden, but did significantly increase hippocampal levels of soluble Aβ42 and reduced hippocampal colocalization of Iba1 and 6E10 in a subset of microglia in close proximity to plaques. Conclusion This work suggests that rather than reducing inflammation per se, microglial p38α inhibition in the context of early AD‐type amyloid pathology may alter hippocampal microglia‐plaque interactions. Additionally, these results support future investigations of microglial p38α signaling at different stages of disease, as well as the potential relationship between p38α and phagocytic processes in this particular cell‐type. Funding : This work is supported by the National Institutes of Health (RF1 AG064859; F32 AG058456; T32 AG057461).

P38mapk: Novel Therapeutic Target to Slow the Progression of Alzheimers Disease

p38α Mitogen-Activated Protein Kinase—An Emerging Drug Target for the Treatment of Alzheimer's Disease

Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease

Involvement of p38 MAPK in Synaptic Function and Dysfunction

The P38 Mitogen Activated Protein Kinase Regulates Β-Amyloid Protein Internalization Through the Α7 Nicotinic Acetylcholine Receptor in Mouse Brain.

The p38 mitogen-activated protein kinase signaling pathway is involved in regulating low-density lipoprotein receptor-related protein 1-mediated β-amyloid protein internalization in mouse brain

Natural Products Regulate the P38MAPK Signaling Pathway: A Promising Strategy in the Prevention and Treatment of Alzheimer’s Disease

Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ

Early loss of microglial p38α MAPK in the APPswe/PS1dE9 mouse model of Alzheimer’s disease alters soluble amyloid beta and reduces microglia co‐localization with amyloid plaques without affecting amyloid‐associated pathology

Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives

A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies

Reduction of advanced tau‐mediated memory deficits by the MAP kinase p38γ

Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy

P38 Activation Mediates Amyloid-β Cytotoxicity

[Expression of P38mapk in the Olfactory Bulb of Rats with Alzheimer's Disease].

P2X7 Receptor: an Emerging Target in Alzheimer's Disease

The role of PI3K signaling pathway in Alzheimer's disease

P38 Activation Mediates Amyloid-Beta Cytotoxicity

[Expression of P38mapk in the Hippocampal CA1 Region of Rats with Abeta25-35-induced Alzheimer Disease].

Mitochondrial Dysfunction Triggers Synaptic Deficits Via Activation of P38 MAP Kinase Signaling in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells.

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics